Talecris Biotherapeutics Albumin Products provide all the safety and cost-saving advantages of albumin vs hetastarch (HES) in cardiac surgery.
 |
 |
Sedrakyan et al analyzed a database of more than 19,500 CABG patients and reported a lower incidence of mortality among patients who received albumin during surgery compared to synthetic colloids (2.47% vs 3.03%, respectively).1
"Albumin use appears to be associated with [a 25%] lower incidence of mortality after coronary bypass graft (CABG) surgery compared to nonprotein colloid use."1
|
|
A meta-analysis that looked at cumulative blood loss during the first 24 hours after cardiopulmonary bypass surgery concluded that postoperative blood loss was significantly lower in patients exposed to albumin than the artificial colloid hydroxyethyl starch (HES).2
"The observation of less bleeding in albumin recipients was striking for its consistency, being evident in 88% of randomized comparisons. Albumin resulted in significantly less bleeding than HES in comparisons involving both volume expansion and addition of colloid to the priming fluid."2
|
|
In a 2004 published report of a study of 45 CABG patients, Kuitunen et al concluded that HES use compromises hemostasis due to the formation of a less stable thrombus than with albumin.3 |
|
|
|
References
| 1. |
|
Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest. 2003;123(6):1853-1857. |
| 2. |
|
Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: A Meta-Analysis of Postoperative Bleeding. Ann Thorac Surg. 2001;72:527-534. |
| 3. |
|
Kuitunen AH, Hynynen MJ, Vahtera E, Salmenpera MT. Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg. 2004;98(2):291-297, table of contents. |
|